Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Hospira was created in 2004 as a spin-off from Abbott Laboratories. It essentially comprises Abbott's old Hospital Products division, selling generic injectables, medication delivery systems and infusion products. A major new focus is biosimilars, for which the company has conducted a number of agreements.

While Hospira is a large company, it is not a fast-growing one. This sales figure has barely changed over the past three years. Specialty injectables, which includes the company's many generic lines, account for around one third of total revenues.

Hospira is a leading supplier of generic injectables in the USA, with a product range of 130 generic injectable products in more than 600 dosages and formulations. Therapeutic areas include cardiovascular, anaesthesia, anti-infectives, analgesics and emergency. Hospira generally procures the active pharmaceutical ingredients in these products from third-party suppliers.

In September 2006, Hospira announced a friendly US$2 billion takeover of Mayne Pharma, an Australian generic injectable specialist. The deal will cement Hospira's leading position in the US and extend its presence into other markets. A rival bidder for Mayne never emerged, and the deal was completed in February 2007.